Elmind Capital LP Invests $4.87 Million in BioMarin Pharmaceutical Inc. $BMRN

Posted by Geri Gentry on Jun 18th, 2026

Elmind Capital LP acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 82,000 shares of the biotechnology company’s stock, valued at approximately $4,873,000. BioMarin Pharmaceutical comprises approximately 1.4% of Elmind Capital LP’s portfolio, making the stock its 19th biggest holding.

Other large investors have also modified their holdings of the company. DNB Asset Management AS boosted its stake in shares of BioMarin Pharmaceutical by 13.8% during the 3rd quarter. DNB Asset Management AS now owns 1,274,284 shares of the biotechnology company’s stock worth $69,015,000 after acquiring an additional 154,954 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of BioMarin Pharmaceutical by 312.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,419,067 shares of the biotechnology company’s stock valued at $84,335,000 after purchasing an additional 1,074,929 shares in the last quarter. Braidwell LP purchased a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at $28,596,000. Perpetual Ltd lifted its holdings in shares of BioMarin Pharmaceutical by 425.7% in the fourth quarter. Perpetual Ltd now owns 25,621 shares of the biotechnology company’s stock valued at $1,523,000 after purchasing an additional 20,747 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of BioMarin Pharmaceutical by 134.2% in the third quarter. Fisher Asset Management LLC now owns 31,726 shares of the biotechnology company’s stock valued at $1,718,000 after purchasing an additional 18,181 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $55.02 on Thursday. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28. The business has a fifty day simple moving average of $54.32 and a 200 day simple moving average of $56.42. The firm has a market cap of $10.63 billion, a price-to-earnings ratio of 40.16, a P/E/G ratio of 0.42 and a beta of 0.25.

Insider Activity

In related news, EVP Gregory R. Friberg sold 3,281 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the completion of the sale, the executive vice president directly owned 51,818 shares in the company, valued at approximately $2,790,399.30. This trade represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BMRN. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, May 5th. Loop Capital set a $105.00 target price on BioMarin Pharmaceutical in a report on Monday, March 2nd. Oppenheimer reduced their target price on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a report on Tuesday, February 24th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Wells Fargo & Company increased their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $88.67.

Read Our Latest Research Report on BMRN

About BioMarin Pharmaceutical

(Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.